Protective effect of interferon and polyacrylic acid in newborn mice infected with a lethal dose of vesicular stomatitis virus

Clercq, Erik De; Somer, P. De

doi:10.1016/0024-3205(68)90098-2

Cited by 29 publications

(8 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since the discovery of interferon (Isaacs & Lindenmann, 1957) and the demonstration that it could inhibit replication of a wide variety of viruses in vitro, considerable interest has been generated concerning its potential application as an antiviral agent in vivo (Arvin et al, 1976;Merigan, 1982;Merigan et al, 1968Merigan et al, , 1973Merigan et al, , 1978De Clercq & De Somer, 1968;Douglas & Betts, 1974;Dziewanowska & Pestka, 1982). Although the quantities and purity of interferon were limited, various groups have clearly demonstrated that in at least some virus diseases, treatment with exogenous interferon has a beneficial effect.…”

Section: Introductionmentioning

confidence: 99%

Effect of Bovine 1 Interferon on Bovine Herpesvirus Type 1-induced Respiratory Disease

Babiuk¹,

Ohmann²,

Gifford

et al. 1985

Journal of General Virology

View full text Add to dashboard Cite

SUMMARYTreatment of calves with bovine recombinant c¢1 interferon prior to challenge with bovine herpesvirus type 1 increased the animals' ability to withstand a subsequent Pasteurella haemolytica challenge. The reduction in viral-bacterial synergy observed following interferon treatment did not appear to be due to a direct effect of the interferon on virus replication in the upper respiratory tract. Thus, even though interferon-treated animals shed slightly less virus from their nasal passages than did untreated animals, this reduction was not statistically significant. Furthermore, there was no difference in the level of intranasal interferon secreted by control or interferontreated animals. These results suggest that interferon treatment does not affect the production of endogenous interferon. In contrast, a significant difference was observed between the number of days that control animals were sick, the levels of serum fibrinogen and the functional activity of polymorphonuclear neutrophilic granulocytes obtained from infected calves. These results suggest that bovine recombinant ~1 interferon may have a greater immunomodulatory effect than a direct antiviral effect in this model. This is further supported by the observation that bovine herpesvirus type 1 is relatively resistant to the direct antiviral effect of bovine recombinant ~1 interferon in vitro.

show abstract

Section: Introductionmentioning

confidence: 99%

Effect of Bovine 1 Interferon on Bovine Herpesvirus Type 1-induced Respiratory Disease

Babiuk¹,

Ohmann²,

Gifford

et al. 1985

Journal of General Virology

View full text Add to dashboard Cite

show abstract

“…That IFN may be effective in the treatment of filovirus (i.e., Ebola virus) infections could be anticipated from our initial results [43] on the protective effects obtained with IFN and IFN inducers (such as PAA) in newborn mice infected with VSV, a rhabdovirus related to the filoviruses. In fact, VSV could be considered a surrogate virus of the filoviruses, in that anti-VSV activity may be predictive of activity against filoviruses.…”

Section: Ifn In the Potential Treatment Of Filovirus Infectionsmentioning

confidence: 96%

Interferon and Its Inducers—A Never-Ending Story: “Old” and “New” Data in a New Perspective

Clercq

2006

The Journal of Infectious Diseases

View full text Add to dashboard Cite

“…Again, it should be mentioned that VSV would serve as an adequate surrogate virus to judge the potential of favipiravir in the treatment of EBOV infections. An in vivo animal model for VSV infection in newborn mice has been described many years ago [51].…”

Section: Favipiravir (T-705)mentioning

confidence: 99%

Ebola virus (EBOV) infection: Therapeutic strategies

Clercq

2015

Biochemical Pharmacology

View full text Add to dashboard Cite

Within less than a year after its epidemic started (in December 2013) in Guinea, Ebola virus (EBOV), a member of the filoviridae, has spread over a number of West-African countries (Guinea, Sierra Leone and Liberia) and gained allures that have been unprecedented except by human immunodeficiency virus (HIV). Although EBOV is highly contagious and transmitted by direct contact with body fluids, it could be counteracted by the adequate chemoprophylactic and -therapeutic interventions: vaccines, antibodies, siRNAs (small interfering RNAs), interferons and chemical substances, i.e. neplanocin A derivatives (i.e. 3-deazaneplanocin A), BCX4430, favipiravir (T-705), endoplasmic reticulum (ER) α-glucosidase inhibitors and a variety of compounds that have been found to inhibit EBOV infection blocking viral entry or by a mode of action that still has to be resolved. Much has to be learned from the mechanism of action of the compounds active against VSV (vesicular stomatitis virus), a virus belonging to the rhabdoviridae, that in its mode of replication could be exemplary for the replication of filoviridae.

show abstract

Protective effect of interferon and polyacrylic acid in newborn mice infected with a lethal dose of vesicular stomatitis virus

Cited by 29 publications

References 9 publications

Effect of Bovine 1 Interferon on Bovine Herpesvirus Type 1-induced Respiratory Disease

Effect of Bovine 1 Interferon on Bovine Herpesvirus Type 1-induced Respiratory Disease

Interferon and Its Inducers—A Never-Ending Story: “Old” and “New” Data in a New Perspective

Ebola virus (EBOV) infection: Therapeutic strategies

Contact Info

Product

Resources

About